FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894764110> ?p ?o ?g. }

• W2894764110 endingPage "606" @default.
• W2894764110 startingPage "598" @default.
• W2894764110 abstract "The prognosis of patients with gastric cancer with bulky node metastasis, linitis plastica (type 4), or large ulcero-invasive-type tumors (type 3) remains poor. We conducted a phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 (DCS) for establishing a new treatment modality that improves prognosis. Patients received up to four 28-day cycles of DCS therapy (docetaxel at 40 mg/m2, cisplatin at 60 mg/m2 on day 1, and S-1 at 40 mg/m2 twice daily for 2 weeks) followed by gastrectomy with D2 nodal dissection. S-1 chemotherapy was administered for 1 year after surgical resection. The primary endpoint was the percentage of complete resections of the primary tumor with clear margins (R0 resection). The planned sample size was 40; this was calculated based on an expected R0 rate of 85% and a threshold R0 rate of 65%, with a one-sided alpha of 5% and a power of 90%. Between 2010 and 2017, 40 patients were enrolled. The R0 resection rate was 90%. The most common grade 3 or 4 adverse events during DCS therapy were leukocytopenia (27.5%), neutropenia (55.0%), and hyponatremia (22.5%). The most common grade 3 or 4 surgical morbidity was pancreatic fistula (12.5%); mortality was 0%. The pathological response rate was 57.5% with a grade 3 histological response rate of 8%. Neoadjuvant chemotherapy with DCS was feasible and showed a sufficient R0 resection rate. A future study with a sufficient follow-up period should confirm survival outcomes." @default.
• W2894764110 created "2018-10-12" @default.
• W2894764110 creator A5011441657 @default.
• W2894764110 creator A5013128552 @default.
• W2894764110 creator A5017811687 @default.
• W2894764110 creator A5018208537 @default.
• W2894764110 creator A5025670560 @default.
• W2894764110 creator A5039267092 @default.
• W2894764110 creator A5040745867 @default.
• W2894764110 creator A5044136552 @default.
• W2894764110 creator A5049017058 @default.
• W2894764110 creator A5061941577 @default.
• W2894764110 creator A5062735277 @default.
• W2894764110 creator A5065961751 @default.
• W2894764110 creator A5068425977 @default.
• W2894764110 creator A5071422219 @default.
• W2894764110 creator A5073508224 @default.
• W2894764110 creator A5090273056 @default.
• W2894764110 date "2018-10-03" @default.
• W2894764110 modified "2023-10-05" @default.
• W2894764110 title "A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial" @default.
• W2894764110 cites W1757407923 @default.
• W2894764110 cites W2019784733 @default.
• W2894764110 cites W2067465377 @default.
• W2894764110 cites W2082189234 @default.
• W2894764110 cites W2089067759 @default.
• W2894764110 cites W2094100986 @default.
• W2894764110 cites W2107602551 @default.
• W2894764110 cites W2115072149 @default.
• W2894764110 cites W2122866527 @default.
• W2894764110 cites W2141592118 @default.
• W2894764110 cites W2234149786 @default.
• W2894764110 cites W2395258738 @default.
• W2894764110 cites W2436775948 @default.
• W2894764110 cites W2572527821 @default.
• W2894764110 cites W2600342108 @default.
• W2894764110 cites W2727515049 @default.
• W2894764110 cites W2891447236 @default.
• W2894764110 cites W2892062705 @default.
• W2894764110 cites W2919030892 @default.
• W2894764110 cites W4231021828 @default.
• W2894764110 cites W4246328459 @default.
• W2894764110 cites W2604692321 @default.
• W2894764110 doi "https://doi.org/10.1007/s10120-018-0884-0" @default.
• W2894764110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30284080" @default.
• W2894764110 hasPublicationYear "2018" @default.
• W2894764110 type Work @default.
• W2894764110 sameAs 2894764110 @default.
• W2894764110 citedByCount "18" @default.
• W2894764110 countsByYear W28947641102019 @default.
• W2894764110 countsByYear W28947641102020 @default.
• W2894764110 countsByYear W28947641102021 @default.
• W2894764110 countsByYear W28947641102022 @default.
• W2894764110 countsByYear W28947641102023 @default.
• W2894764110 crossrefType "journal-article" @default.
• W2894764110 hasAuthorship W2894764110A5011441657 @default.
• W2894764110 hasAuthorship W2894764110A5013128552 @default.
• W2894764110 hasAuthorship W2894764110A5017811687 @default.
• W2894764110 hasAuthorship W2894764110A5018208537 @default.
• W2894764110 hasAuthorship W2894764110A5025670560 @default.
• W2894764110 hasAuthorship W2894764110A5039267092 @default.
• W2894764110 hasAuthorship W2894764110A5040745867 @default.
• W2894764110 hasAuthorship W2894764110A5044136552 @default.
• W2894764110 hasAuthorship W2894764110A5049017058 @default.
• W2894764110 hasAuthorship W2894764110A5061941577 @default.
• W2894764110 hasAuthorship W2894764110A5062735277 @default.
• W2894764110 hasAuthorship W2894764110A5065961751 @default.
• W2894764110 hasAuthorship W2894764110A5068425977 @default.
• W2894764110 hasAuthorship W2894764110A5071422219 @default.
• W2894764110 hasAuthorship W2894764110A5073508224 @default.
• W2894764110 hasAuthorship W2894764110A5090273056 @default.
• W2894764110 hasBestOaLocation W28947641101 @default.
• W2894764110 hasConcept C121608353 @default.
• W2894764110 hasConcept C126322002 @default.
• W2894764110 hasConcept C141071460 @default.
• W2894764110 hasConcept C143998085 @default.
• W2894764110 hasConcept C2776694085 @default.
• W2894764110 hasConcept C2778292576 @default.
• W2894764110 hasConcept C2780140570 @default.
• W2894764110 hasConcept C2780470880 @default.
• W2894764110 hasConcept C2781190966 @default.
• W2894764110 hasConcept C2909463153 @default.
• W2894764110 hasConcept C530470458 @default.
• W2894764110 hasConcept C71924100 @default.
• W2894764110 hasConcept C90924648 @default.
• W2894764110 hasConceptScore W2894764110C121608353 @default.
• W2894764110 hasConceptScore W2894764110C126322002 @default.
• W2894764110 hasConceptScore W2894764110C141071460 @default.
• W2894764110 hasConceptScore W2894764110C143998085 @default.
• W2894764110 hasConceptScore W2894764110C2776694085 @default.
• W2894764110 hasConceptScore W2894764110C2778292576 @default.
• W2894764110 hasConceptScore W2894764110C2780140570 @default.
• W2894764110 hasConceptScore W2894764110C2780470880 @default.
• W2894764110 hasConceptScore W2894764110C2781190966 @default.
• W2894764110 hasConceptScore W2894764110C2909463153 @default.
• W2894764110 hasConceptScore W2894764110C530470458 @default.
• W2894764110 hasConceptScore W2894764110C71924100 @default.
• W2894764110 hasConceptScore W2894764110C90924648 @default.

• next